XLO
Xilio Therapeutics, Inc.
$8.25
-0.33
(-3.79%)
Mkt Cap
49.36M
Volume
58,423
52W Range
6.468-16.1
Sector
Healthcare
Beta
-0.13
EPS (TTM)
-5.50
P/E Ratio
-21.38
Revenue (TTM)
53.48M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 43.77M | 6.34M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.04M) | (58.24M) | (76.40M) | (88.22M) | (75.80M) | (55.22M) | (17.31M) |
| EPS | -4.19 | -15.26 | -38.92 | -45.08 | -189.28 | -1475.88 | -592.06 |
| Free Cash Flow | (5.51M) | (18.41M) | (69.11M) | (77.59M) | (81.85M) | (38.28M) | (18.56M) |
| FCF / Share | -0.07 | -4.82 | -35.19 | -39.66 | -204.40 | -1023.15 | -634.79 |
| Operating CF | (4.99M) | (18.38M) | (68.62M) | (75.72M) | (80.75M) | (36.09M) | (17.84M) |
| Total Assets | 154.69M | 71.08M | 60.93M | 139.16M | 221.60M | 36.32M | 62.72M |
| Total Debt | 6.95M | 8.14M | 11.46M | 19.94M | 20.74M | 21.89M | 18.63M |
| Cash & Equiv | 137.53M | 55.29M | 44.70M | 120.39M | 198.05M | 19.24M | 48.84M |
| Book Value | 35.27M | 17.60M | 36.83M | 105.65M | 185.43M | (5.29M) | 38.51M |
| Return on Equity | -0.99 | -3.31 | -2.07 | -0.84 | -0.41 | N/A | -0.45 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.65M | 13.69M | 19.07M | 8.08M | 2.93M | 1.72M | 2.26M | 2.36M | 0 | 0 | 0 | 0 |
| Net Income | (9.53M) | 10.36M | (16.29M) | (15.84M) | (13.27M) | (13.09M) | (14.02M) | (13.93M) | (17.20M) | (17.66M) | (16.75M) | (19.36M) |
| EPS | -0.58 | 0.96 | -1.54 | -4.34 | -2.52 | -2.80 | -3.08 | -4.48 | -8.68 | -8.96 | -8.54 | -9.80 |
| Free Cash Flow | (22.90M) | (2.09M) | (17.50M) | (14.88M) | 28.96M | (14.16M) | (13.68M) | 19.93M | (10.50M) | (13.43M) | (13.37M) | (16.89M) |
| FCF / Share | -0.14 | -0.03 | -1.70 | -4.02 | 5.43 | -3.07 | -3.02 | 6.35 | -5.27 | -6.82 | -6.80 | -8.61 |
| Operating CF | (22.34M) | (2.00M) | (17.50M) | (14.48M) | 28.98M | (14.16M) | (13.67M) | 19.95M | (10.50M) | (13.43M) | (13.37M) | (16.57M) |
| Total Assets | 163.49M | 154.69M | 133.69M | 133.81M | 103.72M | 71.08M | 74.66M | 89.87M | 82.61M | 60.93M | 77.84M | 92.36M |
| Total Debt | 6.64M | 6.95M | 7.26M | 7.57M | 7.86M | 8.14M | 8.41M | 8.69M | 8.94M | 11.46M | 14.45M | 16.81M |
| Cash & Equiv | 150.33M | 137.53M | 103.76M | 121.55M | 89.07M | 55.29M | 61.26M | 74.95M | 33.98M | 44.70M | 59.77M | 75.38M |
| Book Value | 72.55M | 35.27M | (8.10M) | 7.07M | 10.70M | 17.60M | 20.97M | 33.42M | 25.77M | 36.83M | 52.50M | 67.38M |
| Return on Equity | -0.13 | 0.29 | N/A | -2.24 | -1.24 | -0.74 | -0.67 | -0.42 | -0.67 | -0.48 | -0.32 | -0.29 |
XLO News
Cancer Stocks That Are Advancing the Future of Oncology Care
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market